Article Sidebar

pdf
Date Published: 01/07/2025
Abstract Views: 149
Views pdf: 58
DOI: https://doi.org/10.51298/vmj.v551i3.14777
Issue
Vol. 551 No. 3 (2025)
Section
Các bài báo
How to Cite
Bùi Ngọc, L., & Nguyễn Minh, T. (2025). PALLIATIVE TREATMENT EFFICACY OF CARBOPLATIN IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA AT VIETNAM NATIONAL CHILDREN’S HOSPITAL. Vietnam Medical Journal, 551(3). https://doi.org/10.51298/vmj.v551i3.14777

PALLIATIVE TREATMENT EFFICACY OF CARBOPLATIN IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA AT VIETNAM NATIONAL CHILDREN’S HOSPITAL

Lan Bùi Ngọc, Trang Nguyễn Minh

Main Article Content

Abstract

Objective: To evaluate the palliative effectiveness of Carboplatin in treating high-risk neuroblastoma in pediatric patients at the Vietnam National Children’s Hospital. Subject and method: This retrospective study included 43 children diagnosed with high-risk neuroblastoma between 2022 and 2023 who received monthly Carboplatin infusions at a dose of 560 mg/m². Clinical symptoms, tumor size changes, overall survival (OS), and treatment-related side effects were assessed based on medical records. Results: Most patients observed significant improvement in clinical symptoms following two cycles of palliative treatment. A total of 65.5% showed partial tumor response, including 13.9% with a tumor size reduction of over 90%. The 12-month OS was 41.9%, with better outcomes in patients without Hutchinson syndrome. Main adverse effects included mild anemia and thrombocytopenia, with no severe toxicity recorded. Conclusion: Carboplatin demonstrated acceptable effectiveness and safety in the palliative treatment of high-risk neuroblastoma in children, particularly in resource-limited settings.

Article Details

Keywords

high-risk neuroblastoma, palliative treatment, carboplatin, Vietnam National Children’s Hospital

References

1. Tas ML, Reedijk AMJ, Karim-Kos HE, Kremer LCM, van de Ven CP, Dierselhuis MP, van Eijkelenburg NKA, van Grotel M, Kraal KCJM, Peek AML, Coebergh JWW, Janssens GOR, de Keizer B, de Krijger RR, Pieters R, Tytgat GAM, van Noesel MM. Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. Eur J Cancer, 2020, 124: 47–55.
2. Phùng Tuyết Lan (2008). Nghiên cứu một số đặc điểm lâm sàng, cận lâm sàng và điều trị u nguyên bào thần kinh ở trẻ em. Luận án Tiến sĩ Y học, Trường Đại học Y Hà Nội, Hà Nội.
3. Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, Grabow D, Nolte S, Crazzolara R, Greil J, Ebinger M, Abele M, Holzer U, Döring M, Schulte JH, Bader P, Schlegel PG, Eyrich M, Lang P, Klingebiel T, Handgretinger R. Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study. Cancers (Basel), 2025, 17(1): 149.
4. Andrew M.D. Neuroblastoma. Semin Pediatr Surg, 2013, 21(1): 2–14.
5. Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol, 2015, 33(27): 3008–3017.
6. Wendy BL, Rochelle B, Brenda JW, et al. Historical Time to Disease Progression and Progression-Free Survival in Patients With Recurrent/Refractory Neuroblastoma Treated in the Modern Era on Children’s Oncology Group Early-Phase Trials. Wiley Online Library, 2017, 4914–4923.
7. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol, 2009, 27(2): 298–303.
8. Ojha RP, et al. Survival of high-risk pediatric neuroblastoma patients in a developing country: A retrospective cohort study. Pediatr Transplant, 2016, 20(6): 783–789.
9. Zhu J, Wang J, Zhen ZJ, et al. Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment. Chin J Cancer, 2015, 34(11): 531–537.
10. Brian HK, Kramer K, NaiKong VC. Oral Etoposide for Refractory and Relapsed Neuroblastoma. J Clin Oncol, 1999, 17: 3221–3225.